Quick Answer
Lineage Cell Therapeutics, Inc. reported Total Revenue of $14.56 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed an increase of +53.2% in Total Revenue from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $780.4 thousand | Q3 2011: $1.16 million | Q2 2012: $1.03 million | Q3 2012: $1.00 million | Q2 2017: $381.0 thousand | Q3 2017: $1.69 million | Q2 2018: $2.55 million | Q3 2018: $982.0 thousand | Q1 2020: $514.0 thousand | Q2 2020: $386.0 thousand | Q3 2020: $571.0 thousand | Q4 2020: $355.0 thousand | Q1 2021: $391.0 thousand | Q2 2021: $512.0 thousand | Q3 2021: $2.27 million | Q4 2021: $1.17 million | Q1 2022: $5.24 million | Q2 2022: $4.55 million | Q3 2022: $3.00 million | Q3 2022: $3.00 million | Q4 2022: $1.92 million | Q1 2023: $2.39 million | Q1 2023: $2.39 million | Q2 2023: $3.23 million | Q2 2023: $3.23 million | Q3 2023: $1.25 million | Q1 2024: $1.44 million | Q2 2024: $1.41 million | Q3 2024: $3.78 million | Q1 2025: $1.50 million | Q2 2025: $2.77 million | Q3 2025: $3.68 million.
- Over the full 7 years of available data (2020 to 2025), Lineage Cell Therapeutics, Inc.'s Total Revenue has grown by 697.2%.
- Historical annual values: Fiscal year 2025: $14.56 million | Fiscal year 2024: $9.50 million | Fiscal year 2023: $8.95 million | Fiscal year 2022: $14.70 million | Fiscal year 2022: $14.70 million | Fiscal year 2021: $4.34 million | Fiscal year 2020: $1.83 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: